Lung Cancer

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment sequencing in ROS1-positive non–small cell lung cancer.

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss the prevalence of ROS1 fusions in non–small cell lung cancer.

Ivonescimab plus chemotherapy improved PFS vs chemotherapy alone in second- and later-line EGFR-mutated non–small cell lung cancer.

The BLA seeking the approval of patritumab deruxtecan in EGFR-mutated non–small cell lung cancer has been voluntarily withdrawn.

Panelists discuss how advanced radiotherapy techniques, including stereotactic body radiation therapy (SBRT), combined with immunotherapy, have emerged as preferred treatment approaches for unresectable early-stage non–small cell lung cancer (NSCLC).

Panelists discuss how the diagnostic workup for unresectable stage III non–small cell lung cancer (NSCLC) requires comprehensive staging including imaging studies (PET-CT, brain MRI), tissue sampling through bronchoscopy or endobronchial ultrasound (EBUS), molecular and biomarker testing, and multidisciplinary evaluation to guide optimal treatment planning.

The FDA granted priority review to sevabertinib for pretreated, advanced non–small cell lung cancer harboring HER2 mutations.

Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib.

A 2025 ASCO press briefing previewed key advances in breast and lung cancer, HER2 diagnostics, and GLP-1s’ link to reduced cancer risk.

Panelists discuss how implementing the new standard of combination therapies requires thorough patient education, prophylactic management of toxicities, and multidisciplinary support to optimize outcomes for patients with EGFR-mutant lung cancer.

Panelists discuss how optimizing treatment duration, using local therapy for oligometastatic disease, and understanding the limitations of current biomarkers are important considerations in developing effective sequencing strategies for EGFR-mutant lung cancer.

Panelists discuss how central nervous system (CNS) progression presents unique challenges in treatment decision-making, highlighting the importance of brain imaging surveillance and considering approaches that maintain CNS disease control while addressing systemic progression.

IMforte data highlight potential for lurbinectedin plus atezolizumab to become a new SOC for first-line maintenance treatment in ES-SCLC.

Osimertinib, with conditions, has been approved by Health Canada for locally advanced, unresectable NSCLC, harboring EGFR mutations.

The FDA granted breakthrough device designation to EnVisio X1 for minimally invasive surgery in cancer care.

Panelists discuss how to treat patients who do not achieve a pathological complete response or major pathological response after neoadjuvant chemoimmunotherapy, considering options such as adjuvant therapy, close surveillance, or clinical trial enrollment based on individual risk factors and disease characteristics.

Panelists discuss how circulating tumor DNA could serve as a potential marker for minimal residual disease (MRD) in this setting, offering a noninvasive and sensitive method for monitoring treatment response and detecting relapse.

The DLL3-targeted antibody-drug conjugate ZL-1310 has received FDA fast track designation for patients with extensive-stage small cell lung cancer.

The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.

First-line cemiplimab extended median PFS and OS vs chemotherapy in patients with untreated advanced NSCLC with brain metastases.

Perioperative nivolumab plus chemotherapy was approved by the European Commission for use in resectable PD-L1–positive non–small cell lung cancer.

Panelists discuss how many patients never receive second-line therapy, emphasizing the critical importance of selecting the optimal first-line treatment and monitoring patients closely to identify progression early.